Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markman

Showing results (301-310 of 1,623) with videos related to

Pageof 163
Sort By:
Lancet (London, England)|November 17, 1984
No increase in allergic reactions with intracavitary administration of cisplatinM Markman
Gynecologic Oncology|December 1, 1994
Follow-up of the asymptomatic patient with ovarian cancerM Markman
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 11, 2008
Strategies to examine new compounds for intraperitoneal use in ovarian cancerM Markman
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 11, 2008
What is the optimal approach to the administration of intraperitoneal chemotherapy in ovarian cancer?M Markman
Oncology|January 22, 2008
The rapidly changing oncology landscape: a time for transition in oncologyMaurie Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1994
Revisiting the debate: the use of new agents in previously untreated patients with small cell lung cancer; quality versus duration of survivalM Markman
Nature Clinical Practice. Oncology|September 5, 2007
The CA125 antigen level as a prognostic versus a predictive test in epithelial ovarian cancerMaurie Markman
Oncology|July 25, 2007
Efforts to define a role for recombinant erythropoietin in cancer managementMaurie Markman
Gynecologic Oncology|July 31, 2007
Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trialsMaurie Markman
Cancer|September 20, 2007
Differences between a drug regimen employed in early phase 1 trials and the subsequent use of the agent in routine oncologic practice: a note of cautionMaurie Markman
Pageof 163

Showing results (301-310 of 1,623) with videos related to

Sort By:
Pageof 163
Lancet (London, England)|November 17, 1984
No increase in allergic reactions with intracavitary administration of cisplatinM Markman
Gynecologic Oncology|December 1, 1994
Follow-up of the asymptomatic patient with ovarian cancerM Markman
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 11, 2008
Strategies to examine new compounds for intraperitoneal use in ovarian cancerM Markman
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 11, 2008
What is the optimal approach to the administration of intraperitoneal chemotherapy in ovarian cancer?M Markman
Oncology|January 22, 2008
The rapidly changing oncology landscape: a time for transition in oncologyMaurie Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1994
Revisiting the debate: the use of new agents in previously untreated patients with small cell lung cancer; quality versus duration of survivalM Markman
Nature Clinical Practice. Oncology|September 5, 2007
The CA125 antigen level as a prognostic versus a predictive test in epithelial ovarian cancerMaurie Markman
Oncology|July 25, 2007
Efforts to define a role for recombinant erythropoietin in cancer managementMaurie Markman
Gynecologic Oncology|July 31, 2007
Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trialsMaurie Markman
Cancer|September 20, 2007
Differences between a drug regimen employed in early phase 1 trials and the subsequent use of the agent in routine oncologic practice: a note of cautionMaurie Markman
Pageof 163